Topical Calcipotriol Plus 5-Fluorouracil Immunotherapy for Actinic Keratosis Treatment

Marjan Azin^{1

2

3}, Andrew B Mahon⁴, Steven Isaacman⁴, Julia E Seaman⁵, Isabel E Allen^{5

6}, Michael Szarek^{7

8

9}, Lynn A Cornelius¹⁰, Shadmehr Demehri^{1

2

3}

Affiliations

¹ Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Center for Cancer Immunology, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³ Center for Cancer Research, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁴ PHD Biosciences, San Diego, California, USA.
⁵ Bay View Analytics, Oakland, California, USA.
⁶ Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
⁷ School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
⁸ CPC Clinical Research, Aurora, Colorado, USA.
⁹ Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
¹⁰ Division of Dermatology, John T. Milliken Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

Marjan Azin et al. JID Innov. 2022.

. 2022 Jan 29;2(3):100104.

doi: 10.1016/j.xjidi.2022.100104. eCollection 2022 May.

Marjan Azin^{1

2

3}, Andrew B Mahon⁴, Steven Isaacman⁴, Julia E Seaman⁵, Isabel E Allen^{5

6}, Michael Szarek^{7

8

9}, Lynn A Cornelius¹⁰, Shadmehr Demehri^{1

2

3}

¹ Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Center for Cancer Immunology, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³ Center for Cancer Research, Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁴ PHD Biosciences, San Diego, California, USA.
⁵ Bay View Analytics, Oakland, California, USA.
⁶ Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
⁷ School of Public Health, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
⁸ CPC Clinical Research, Aurora, Colorado, USA.
⁹ Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
¹⁰ Division of Dermatology, John T. Milliken Department of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

No abstract available

Keywords: 5-FU, 5-fluorouracil; AK, actinic keratosis.

Figures

1. Blauvelt A., Kempers S., Lain E., Schlesinger T., Tyring S., Forman S., et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384:512–520. - PubMed
1. Cornejo C.M., Jambusaria-Pahlajani A., Willenbrink T.J., Schmults C.D., Arron S.T., Ruiz E.S. Field cancerization: treatment. J Am Acad Dermatol. 2020;83:719–730. - PubMed
1. Cunningham T.J., Tabacchi M., Eliane J.P., Tuchayi S.M., Manivasagam S., Mirzaalian H., et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2017;127:106–116. - PMC - PubMed
1. Lebwohl M., Swanson N., Anderson L.L., Melgaard A., Xu Z., Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366:1010–1019. - PubMed
1. Rosenberg A.R., Tabacchi M., Ngo K.H., Wallendorf M., Rosman I.S., Cornelius L.A., et al. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight. 2019;4:e125476. - PMC - PubMed